This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-09. Anything still debated is marked as such rather than presented as settled.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or powder |
| Solubility class | Freely soluble in water | Aqueous buffers also used |
| Typical storage temperature | About -20 degrees Celsius | Dry, sealed and protected from light |
| Typical analytical method | Reversed-phase HPLC or LC-MS/MS | Used for purity, identity and quantification |
| Common synonyms | Thymosin beta-4 fragment | Also listed under fragment-based descriptions |
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
=== Soluble (sRAGE) === The soluble form of RAGE (sRAGE) only includes the extracellular domain and lacks both the transmembrane and cytoplasmic domains. sRAGE can be generated through two primary mechanisms:
Teva holds patents on multiple drugs, including Copaxone, a specialty drug (for the treatment of multiple sclerosis), now the world's best selling MS drug, and Azilect (sold as Agilect in some countries) for treatment of Parkinson's disease. By July 2015, Copaxone held a "31.2 percent shares of total MS prescriptions in the United States." Teva's new 40 mg version of Copaxone taken three times a week "accounted for 68.5 percent of total Copaxone prescriptions in the United States." Copaxone accounts for about fifty percent of "Teva's profit and 20 percent of revenue." Competitors' Glatopa, 20 mg version of Copaxone, is taken once a day. In June 2006, Teva received from the FDA a 180-day exclusivity period to sell simvastatin (Zocor) in the U.S. as a generic drug in all strengths except 80 mg. Teva presently competes with the maker of brand-name Zocor, Merck & Co.; Ranbaxy Laboratories, which has 180-day exclusivity for the 80 mg strength; and Dr. Reddy's Laboratories, whose authorized generic version (licensed by Merck) is exempt from exclusivity. In June 2010, the company announced it would discontinue its production of propofol, a major sedative estimated to be used in 75% of all US anesthetic procedures. In March 2015, Teva sold four anti-cancer compounds to Ignyta Inc. for $41.6 million. As part of the deal Teva sold the following compounds which were then renamed:
== Structure == Relaxin-3 consists of 51 amino acids in humans which are arranged into a two-chain structure (designated the A-chain and B-chain). There are three disulfide bonds (two interchain, one intrachain), with the residues that mediate binding to/activation of RXFP3 residing within the B-chain. At translation, pro-relaxin-3 also contains a C-chain (in between the A and B-chains) which is removed via protolytic cleavage to form the mature neuropeptide.
In addition, numerous auxiliary formations were trained as support units capable of occupying strategic border areas, including the predominantly Angolan 32 Battalion, Namibia's South West African Territorial Force, and four (Bophuthatswana, Ciskei, Transkei, and Venda) Bantustan militaries.
== Role in protection against oxidative stress == Aerobic bacteria inevitably are prone to the formation of reactive oxygen species due to the nature of their respiration processes. Under normal conditions these ROS strive to maintain a dynamic balance; however, this balance can often be disrupted by biotic or abiotic stressors such as superoxide radicals, endogenous lipids, DNA hydroperoxides, hydrogen peroxide, hydroxyl radicals, and hydroxy alkenals. Therefore, these susceptible organisms have intrinsic mechanisms to protect from oxidative damage; glutathione plays a key role in most of these antioxidant mechanisms. Once reduced, glutathione interacts with these reactive oxygen and nitrogen species. This interaction is catalyzed by GSTs and their involvement is vital for successful oxidation of glutathione. GSTs bind the ROS substrate at its hydrophobic alpha-helical C-terminal domain, as well as reduced glutathione to its glutathione-binding site on the N-terminal domain. These two domains are adjacent to each other on the enzyme, and together form the active site of the GST where the redox reaction occurs. Once both substrates are bound at the enzyme's active site, the monomeric GST interacts with another substrate-bound GST monomer and catalyzes a disulphide bridge between the two glutathione molecules. This yields the active dimeric enzyme structure. The reactive oxygen species then donates one electron to a glutathione molecule, completing the oxidation-reduction reaction and rendering it unable to perform oxidative damage to the cell.
Sources: en.wikipedia.org
==== MeSH E05.318.308 – data collection ==== MeSH E05.318.308.225 – geriatric assessment MeSH E05.318.308.250 – health surveys MeSH E05.318.308.250.149 – behavioral risk factor surveillance system MeSH E05.318.308.250.300 – dental health surveys MeSH E05.318.308.250.300.300 – dental plaque index MeSH E05.318.308.250.300.350 – dmf index MeSH E05.318.308.250.300.675 – oral hygiene index MeSH E05.318.308.250.300.725 – periodontal index MeSH E05.318.308.250.475 – health status indicators MeSH E05.318.308.250.475.365 – apache MeSH E05.318.308.250.475.547 – severity of illness index MeSH E05.318.308.250.475.547.500 – karnofsky performance status MeSH E05.318.308.250.475.730 – sickness impact profile MeSH E05.318.308.250.580 – mass screening MeSH E05.318.308.250.580.174 – anonymous testing MeSH E05.318.308.250.580.350 – genetic screening MeSH E05.318.308.250.580.510 – mass chest x-ray MeSH E05.318.308.250.580.560 – multiphasic screening MeSH E05.318.308.250.580.580 – neonatal screening MeSH E05.318.308.250.580.925 – vision screening MeSH E05.318.308.250.600 – nutrition surveys MeSH E05.318.308.250.600.350 – diet surveys MeSH E05.318.308.250.700 – population surveillance MeSH E05.318.308.250.700.650 – sentinel surveillance MeSH E05.318.308.335 – health care surveys MeSH E05.318.308.420 – interviews MeSH E05.318.308.420.200 – focus groups MeSH E05.318.308.502 – narration MeSH E05.318.308.585 – nutrition assessment MeSH E05.318.308.585.550 – nutrition surveys MeSH E05.318.308.585.550.350 – diet surveys MeSH E05.318.308.750 – questionnaires MeSH E05.318.308.940 – records MeSH E05.318.308.940.250 – birth certificates MeSH E05.318.308.940.350 – death certificates MeSH E05.318.308.940.375 – dental records MeSH E05.318.308.940.425 – hospital records MeSH E05.318.308.940.968 – medical records MeSH E05.318.308.940.968.500 – medical record linkage MeSH E05.318.308.940.968.625 – medical records systems, computerized MeSH E05.318.308.940.968.750 – medical records, problem-oriented MeSH E05.318.308.940.968.875 – trauma severity indices MeSH E05.318.308.940.968.875.125 – abbreviated injury scale MeSH E05.318.308.940.968.875.250 – glasgow coma scale MeSH E05.318.308.940.968.875.260 – glasgow outcome scale MeSH E05.318.308.940.968.875.500 – injury severity score MeSH E05.318.308.940.984 – nursing records MeSH E05.318.308.970 – registries MeSH E05.318.308.970.725 – seer program MeSH E05.318.308.985 – vital statistics MeSH E05.318.308.985.450 – life expectancy MeSH E05.318.308.985.475 – life tables MeSH E05.318.308.985.525 – morbidity MeSH E05.318.308.985.525.080 – basic reproduction number MeSH E05.318.308.985.525.375 – incidence MeSH E05.318.308.985.525.750 – prevalence MeSH E05.318.308.985.550 – mortality MeSH E05.318.308.985.550.250 – cause of death MeSH E05.318.308.985.550.287 – child mortality MeSH E05.318.308.985.550.325 – fatal outcome MeSH E05.318.308.985.550.362 – fetal mortality MeSH E05.318.308.985.550.400 – hospital mortality MeSH E05.318.308.985.550.475 – infant mortality MeSH E05.318.308.985.550.500 – maternal mortality MeSH E05.318.308.985.550.900 – survival rate MeSH E05.318.308.985.775 – pregnancy rate MeSH E05.318.308.985.775.500 – birth rate
The stream of protonated water clusters acts as a secondary ionizing species and generates analytes ions by chemical ionization mechanisms at atmospheric pressure. Here protonation, deprotonation, direct charge transfer and adduct ion formation may occur.
== Pharmacokinetics == Although Levonantradol has been extensively tested on animals including cats, rodents, and non-human primates. It has also been tested among cancer patient populations in clinical trials. Levonantradol is most commonly administered intramuscularly (I.M.), however it can also be administered orally. The dosage can range from 0.25 mg-3.0 mg every 2–4 hours, and the half-life is 1–2 hours. In order to administer Levonantradol intramuscularly, the drug must be dissolved in 5% ethanol, 5% emulphur, and 90% sterile saline. Synthetic cannabinoids like Levonantradol readily cross the blood–brain barrier because they are highly lipophilic and have low molecular weights. Levonantradol's bioavailability is variable due to the first pass metabolism.
=== Silk fibroin === Silk fibroin is the load-bearing protein of silkworm silk and the basis of most silk biomaterials. In Bombyx mori it consists of a large heavy chain of about 390 kilodaltons linked by a disulfide bond to a much smaller light chain of about 26 kilodaltons, together with a small glycoprotein. The heavy chain is dominated by long, repetitive runs of three small amino acids: glycine, alanine and serine. These sequences fold into tightly packed, ordered domains known as beta sheets, stabilised by extensive hydrogen bonding and separated by less ordered regions. This arrangement gives silk its unusual combination of stiffness and toughness. Much of a silk material's behaviour depends on these beta-sheet domains—their abundance and their degree of alignment. Solid silk exists in two principal forms: a less stable form, sometimes designated Silk I, and the more stable, crystalline beta-sheet form, Silk II. Most processing is concerned with controlling the conversion between the two, since a higher beta-sheet content produces a material that is stronger, less soluble in water and slower to degrade.
=== Supercritical water gasification === Supercritical water gasification is a process of exploiting the beneficial effect of supercritical water to convert aqueous biomass streams into clean water and gases like H2, CH4, CO2, CO etc.
Sources: en.wikipedia.org
=== Reducing filament evaporation === During ordinary operation, the tungsten of the filament evaporates; hotter, more-efficient filaments evaporate faster. Because of this, the lifetime of a filament lamp is a trade-off between efficiency and longevity. The trade-off is typically set to provide a lifetime of 1,000 to 2,000 hours for lamps used for general illumination. Theatrical, photographic, and projection lamps may have a useful life of only a few hours, trading life expectancy for high output in a compact form. Long-life general service lamps have lower efficiency, but prior to the development of compact fluorescent and LED lamps they were useful in applications where the bulb was difficult to change. Irving Langmuir found that an inert gas, instead of vacuum, would retard evaporation. General service incandescent light bulbs over about 25 watts in rating are now filled with a mixture of mostly argon and some nitrogen, or sometimes krypton. While inert gas reduces filament evaporation, it also conducts heat from the filament, thereby cooling the filament and reducing efficiency. At constant pressure and temperature, the thermal conductivity of a gas depends upon the molecular weight of the gas and the cross sectional area of the gas molecules. Higher molecular weight gases have lower thermal conductivity, because both the molecular weight and cross sectional area are higher. Xenon gas improves efficiency because of its high molecular weight, but is also more expensive, so its use is limited to smaller lamps.
Thermodynamics is concerned with heat and temperature and their relation to energy and work. It defines macroscopic variables, such as internal energy, entropy, and pressure, that partly describe a body of matter or radiation. It states that the behavior of those variables is subject to general constraints common to all materials. These general constraints are expressed in the four laws of thermodynamics. Thermodynamics describes the bulk behavior of the body, not the microscopic behaviors of the very large numbers of its microscopic constituents, such as molecules. The behavior of these microscopic particles is described by, and the laws of thermodynamics are derived from, statistical mechanics. The study of thermodynamics is fundamental to materials science. It forms the foundation to treat general phenomena in materials science and engineering, including chemical reactions, magnetism, polarizability, and elasticity. It explains fundamental tools such as phase diagrams and concepts such as phase equilibrium.
=== Education === Laposata joined the faculty of the University of Pennsylvania School of Medicine as an assistant professor in 1985.[6] In 1989 he became Director of Clinical Laboratories at Massachusetts General Hospital, where he was also on the faculty of Harvard Medical School ultimately as a tenured full professor.[1][6] He moved to Vanderbilt University School of Medicine in 2008 where he was the Pathologist-in-Chief at Vanderbilt University Hospital.[1] He joined the University of Texas Medical Branch in Galveston as professor and chair of the Department of Pathology in 2014. He also directed UTMB's MD-PhD program.[2][5] At all three institutions he built diagnostic management teams to provide ordering physicians an expert's interpretation of complex laboratory results, with recommended next steps.[1] He organized three national conferences on forming diagnostic management teams.[source needed] Laposata retired from academic medicine in September of 2026.
Pentazocine, sold under the brand name Talwin among others, is an opioid analgesic medication used to treat moderate to severe pain. Pentazocine activates (agonizes) κ-opioid receptors (KOR) and μ-opioid receptors (MOR). It shares many of the side effects of other opioids like constipation, nausea, itching, drowsiness, and respiratory depression, but, unlike most other opioids, it fairly frequently causes hallucinations, nightmares, and delusions. It is also, unlike most other opioids, subject to a ceiling effect, which is when at a certain dose no more pain relief is obtained by increasing the dose any further. Chemically it is classed as a benzomorphan and it comes in two enantiomers. It was patented in 1960 and approved for medical use in 1964. Usually, in its oral formulations, it is combined with naloxone so as to prevent people from crushing the tablets, dissolving them in saline and injecting them for a high (as orally administered naloxone produces no opioid-negating effects as it has no oral bioavailability, whereas intravenous or intramuscular administration does).
Sources: en.wikipedia.org
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.
Reported purity reflects the batch tested, the chromatographic method used and whether an independent laboratory performed the work. Values quoted without method detail or a traceable certificate are difficult to compare directly.
Short peptides are rapidly broken down by proteases and appear at low concentrations in urine, so the detection window is narrow. Sensitive extraction combined with tandem mass spectrometry is typically required.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.